The Hartford (CT) Courant (3/1, Rosner) reports, “The number of privately insured women nationwide between the ages of 15 and 44 who filled a prescription for an” attention-deficit/hyperactivity disorder AD/HD “medication soared 344 percent from 2003 to 2015, from 0.9 percent to 4 percent, according to” data from the Centers for Disease Control and Prevention (CDC).
Amphetamine salts, lisdexamfetamine, and methylphenidate are the three commonly filled AD/HD prescriptions, according to the CDC, and all three of those drugs are classified as Category C drugs by the FDA, which means that “studies on animals have shown an adverse effect on a fetus and there are no adequate and well-controlled studies in humans, but potential benefit may warrant their use in pregnancy despite potential risks.”
Related Links:
— “ADHD Drug Use Rises Sharply Among Young Women,” Cara Rosner, , March 1, 2018.